

QS-21 GH (Global Health) Saponin Adjuvant for LMICs Vaccine Development Programs

Derived from a scalable and sustainable Quillaja biomass source

www.spipharma.com



What is QS-21 GH?

QS-21 GH is a purified, affordable QS-21 fraction derived from a scalable, sustainable *Quillaja* biomass source. QS-21 is a key adjuvant in three FDA- and WHO-approved vaccines - Mosquirix[®], Shingrix[®], and Arexvy[®] - and is widely used in vaccine candidates for tuberculosis, hepatitis B, and influenza. QS-21 GH is currently under evaluation in five preclinical studies.



Safety Profile

QS-21 GH is considered suitable for use in vaccine formulations and is intended to be combined with lipids to form an adjuvant system, which may enhance tolerability. Its safety profile is consistent with that of both QS-21 and Fraction C adjuvants.



Built for Global Vaccine Access

QS-21 GH was developed to support vaccines addressing global health priorities, enabling programs focused on affordability, scalability, and broad patient access, including in LMICs.



Open Access Worldwide

QS-21 GH is openly accessible to vaccine developers and manufacturers globally, supporting equitable access to critical adjuvant technologies.



Powerful, Proven Immune Responses

Backed by more than 35 years of QS-21 scientific validation, QS-21 GH is a highly potent immunostimulatory adjuvant. It enhances both humoral and cell-mediated immune responses by activating antigen-presenting cells, improving antigen presentation, and promoting balanced Th1/Th2 cytokine responses. When combined with TLR4 agonists, QS-21 GH acts synergistically to significantly increase vaccine potency.



Reliable, Sustainable Supply at Origin


QS-21 GH is derived from multiple renewable *Quillaja saponaria* biomass sources, including sustainably pruned trees, ensuring environmental and economic sustainability. Q-VANT's fully integrated supply chain in Chile - from biomass management through extraction, purification, and fractionation - ensures consistent quality and full traceability.



Ready Today, Scaled for Tomorrow

- QS-21 GH RUO samples available
- cGMP material available Q3 2026
- RUO samples of T4QGH adjuvant system available

The T4QGH adjuvant system, formulated with QS-21 GH and the TLR4 agonist INI-2002, produced antibody titers and strong Th1-biased immune responses to an influenza antigen comparable to those achieved with the standard QS-21 grade. No differences in injection-site pain were observed, demonstrating comparable performance and tolerability. Overall, T4Q and T4QGH formulations showed equivalent immunogenicity and safety profiles, independent of the QS-21 grade used.



Mosquirix[®], Shingrix[®], Arexvy[®] are trademarks of GlaxoSmithKline. Scientific references available upon request.

Contact one of our experts, we are here to help!



salesinfo@spipharma.com



www.spipharma.com



All information and statements given in this brochure are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and also with all patent or other intellectual property rights of third parties. Valens[™] is a trademark of SPI Pharma. SPI PHARMA EXPRESSLY DISCLAIMS ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AS TO THE ACCURACY, CURRENCY, COMPLETENESS AND/OR THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INFORMATION CONTAINED IN THIS BROCHURE AND/OR ANY PRODUCT DESCRIBED OR PROMOTED IN THIS BROCHURE, INCLUDING WARRANTIES WITH RESPECT TO INFRINGEMENT OF ANY PATENT, COPYRIGHT, OR OTHER RIGHTS OF A THIRD PARTY. We reserve the right to change product specification and not specified properties of the products without prior notice.

All rights reserved. © 2026 SPI Pharma